Meden H, Marx D, Raab T, Kron M, Schauer A, Kuhn W
Department of Obstetrics and Gynecology, University of Göttingen, Germany.
J Obstet Gynaecol (Tokyo 1995). 1995 Apr;21(2):167-78. doi: 10.1111/j.1447-0756.1995.tb01090.x.
The purpose of this study was to investigate the prognostic value of EGF-R (c-erbB-1) compared to the overexpression of the c-erbB-2 oncogene product p185 in ovarian cancer.
The study was conducted on 266 previously untreated ovarian cancer patients with FIGO stage I-IV disease. EGF-R and c-erbB-2 oncogene product p185 have been evaluated using immunohistochemistry. Survival times were analyzed according to the method described by Kaplan and Meier. For the simultaneous evaluation of the prognostic relevance of the analyzed factors, a Cox proportional hazards regression was performed.
EGF-R was detected in 13%, and c-erbB-2 oncogene product p185 in 18% of primary tumors. EGF-R showed no significant impact on the survival time, whereas c-erbB-2 oncogene product p185 positive patients had a significantly worse prognosis compared to p185 negative cases (p = 0.002). In the multivariate analysis, c-erbB-2 oncogene product p185, like tumor stage, histological grade and age, was found to be a significant prognostic factor.
These data confirm the prognostic importance of the c-erbB-2; oncogene product p185 in ovarian cancer at the time of primary surgery, while EGF-R does not seem to have prognostic relevance.
本研究旨在探讨与c-erbB-2癌基因产物p185在卵巢癌中的过表达相比，表皮生长因子受体（EGF-R，c-erbB-1）的预后价值。
本研究针对266例先前未经治疗、国际妇产科联盟（FIGO）分期为I-IV期的卵巢癌患者开展。采用免疫组织化学方法评估EGF-R和c-erbB-2癌基因产物p185。根据Kaplan和Meier描述的方法分析生存时间。为同时评估所分析因素的预后相关性，进行了Cox比例风险回归分析。
在13%的原发性肿瘤中检测到EGF-R，在18%的原发性肿瘤中检测到c-erbB-2癌基因产物p185。EGF-R对生存时间无显著影响，而c-erbB-2癌基因产物p185阳性患者的预后明显比p185阴性患者差（p = 0.002）。在多变量分析中，发现c-erbB-2癌基因产物p185与肿瘤分期、组织学分级和年龄一样，是一个显著的预后因素。
这些数据证实了c-erbB-2癌基因产物p185在初次手术时对卵巢癌的预后重要性，而EGF-R似乎与预后无关。
